Targeting rare tumors: new focus for clinical research in China
Abstract Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2022-11-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202216415 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226041867894784 |
|---|---|
| author | Shuhang Wang Yale Jiang Huilei Miao Yuan Fang Ning Jiang Yue Yu Peiwen Ma Qiyu Tang Dandan Cui Hong Fang Huiyao Huang Qi Fan Chao Sun Anqi Yu Shuangman Miao Jingting Du Jingxiao Zhu Yuning Wang Ning Li |
| author_facet | Shuhang Wang Yale Jiang Huilei Miao Yuan Fang Ning Jiang Yue Yu Peiwen Ma Qiyu Tang Dandan Cui Hong Fang Huiyao Huang Qi Fan Chao Sun Anqi Yu Shuangman Miao Jingting Du Jingxiao Zhu Yuning Wang Ning Li |
| author_sort | Shuhang Wang |
| collection | DOAJ |
| description | Abstract Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for rare tumor patients in China further provided prospects for precise and individualized targeted treatment. An ongoing phase II clinical trial, the PLATFORM study, is the first trial tailored for rare solid tumors in China, featured by molecule‐guided therapeutics. With the promulgation of supportive policies to encourage the development of innovative drugs for rare tumors in China, opportunities will be provided for these patients and the gap will be filled in the treatment of rare tumors. |
| format | Article |
| id | doaj-art-1aec64bcd68642c58834e7e40261dcc9 |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2022-11-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-1aec64bcd68642c58834e7e40261dcc92025-08-24T11:43:29ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842022-11-011511410.15252/emmm.202216415Targeting rare tumors: new focus for clinical research in ChinaShuhang Wang0Yale Jiang1Huilei Miao2Yuan Fang3Ning Jiang4Yue Yu5Peiwen Ma6Qiyu Tang7Dandan Cui8Hong Fang9Huiyao Huang10Qi Fan11Chao Sun12Anqi Yu13Shuangman Miao14Jingting Du15Jingxiao Zhu16Yuning Wang17Ning Li18Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeClinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for rare tumor patients in China further provided prospects for precise and individualized targeted treatment. An ongoing phase II clinical trial, the PLATFORM study, is the first trial tailored for rare solid tumors in China, featured by molecule‐guided therapeutics. With the promulgation of supportive policies to encourage the development of innovative drugs for rare tumors in China, opportunities will be provided for these patients and the gap will be filled in the treatment of rare tumors.https://doi.org/10.15252/emmm.202216415 |
| spellingShingle | Shuhang Wang Yale Jiang Huilei Miao Yuan Fang Ning Jiang Yue Yu Peiwen Ma Qiyu Tang Dandan Cui Hong Fang Huiyao Huang Qi Fan Chao Sun Anqi Yu Shuangman Miao Jingting Du Jingxiao Zhu Yuning Wang Ning Li Targeting rare tumors: new focus for clinical research in China EMBO Molecular Medicine |
| title | Targeting rare tumors: new focus for clinical research in China |
| title_full | Targeting rare tumors: new focus for clinical research in China |
| title_fullStr | Targeting rare tumors: new focus for clinical research in China |
| title_full_unstemmed | Targeting rare tumors: new focus for clinical research in China |
| title_short | Targeting rare tumors: new focus for clinical research in China |
| title_sort | targeting rare tumors new focus for clinical research in china |
| url | https://doi.org/10.15252/emmm.202216415 |
| work_keys_str_mv | AT shuhangwang targetingraretumorsnewfocusforclinicalresearchinchina AT yalejiang targetingraretumorsnewfocusforclinicalresearchinchina AT huileimiao targetingraretumorsnewfocusforclinicalresearchinchina AT yuanfang targetingraretumorsnewfocusforclinicalresearchinchina AT ningjiang targetingraretumorsnewfocusforclinicalresearchinchina AT yueyu targetingraretumorsnewfocusforclinicalresearchinchina AT peiwenma targetingraretumorsnewfocusforclinicalresearchinchina AT qiyutang targetingraretumorsnewfocusforclinicalresearchinchina AT dandancui targetingraretumorsnewfocusforclinicalresearchinchina AT hongfang targetingraretumorsnewfocusforclinicalresearchinchina AT huiyaohuang targetingraretumorsnewfocusforclinicalresearchinchina AT qifan targetingraretumorsnewfocusforclinicalresearchinchina AT chaosun targetingraretumorsnewfocusforclinicalresearchinchina AT anqiyu targetingraretumorsnewfocusforclinicalresearchinchina AT shuangmanmiao targetingraretumorsnewfocusforclinicalresearchinchina AT jingtingdu targetingraretumorsnewfocusforclinicalresearchinchina AT jingxiaozhu targetingraretumorsnewfocusforclinicalresearchinchina AT yuningwang targetingraretumorsnewfocusforclinicalresearchinchina AT ningli targetingraretumorsnewfocusforclinicalresearchinchina |